Press Releases Tracy Lessor 17/4/25 Tracy Lessor 17/4/25 Edgewood Oncology Announces First Patient Dosed in Phase 1 Investigator-Sponsored Study of BTX-A51 in Liposarcoma Read More Tracy Lessor 17/4/25 Tracy Lessor 17/4/25 New Preclinical Data on BTX-A51 in Liposarcoma Models to be Highlighted at AACR Annual Meeting 2025 Read More David Cook 21/5/24 David Cook 21/5/24 Edgewood Oncology Announces First Patients Dosed in Phase 2a Study of BTX-A51 in Genetically-Defined Breast Cancer Read More David Cook 8/4/24 David Cook 8/4/24 Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma Read More David Cook 25/3/24 David Cook 25/3/24 Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors Read More
Tracy Lessor 17/4/25 Tracy Lessor 17/4/25 Edgewood Oncology Announces First Patient Dosed in Phase 1 Investigator-Sponsored Study of BTX-A51 in Liposarcoma Read More
Tracy Lessor 17/4/25 Tracy Lessor 17/4/25 New Preclinical Data on BTX-A51 in Liposarcoma Models to be Highlighted at AACR Annual Meeting 2025 Read More
David Cook 21/5/24 David Cook 21/5/24 Edgewood Oncology Announces First Patients Dosed in Phase 2a Study of BTX-A51 in Genetically-Defined Breast Cancer Read More
David Cook 8/4/24 David Cook 8/4/24 Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma Read More
David Cook 25/3/24 David Cook 25/3/24 Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors Read More
